Facing declining market share in its core generic controlled
substance (painkillers) market and holding the valuable asset of an
Irish tax domicile, Mallinckrodt plc (NYSE: MNK ) has aggressively put its balance sheet to work. First the company announced a $1.3 billion deal for Cadence Pharmaceuticals (NASDAQ: CADX )
and its hospital-centered Ofirmev product (injected acetamenophen).
Now the company is taking an even bigger swing – announcing a $5.6
billion deal for controversial Questcor (NASDAQ: QCOR ) and its lead drug Acthar.
If Mallinckrodt can steer Questcor past the rocks that short
sellers have been loudly claiming are in the company's path, this deal
could double Mallinckrodt's earnings in relatively short order. If the
short sellers are proven right about the many and varied problems of
Questcor and Acthar, Mallinckrodt's shareholders will pay the price.
Read more here:
Mallinckrodt plc Takes a Big Swing for Growth
Showing posts with label Cadence. Show all posts
Showing posts with label Cadence. Show all posts
Tuesday, April 8, 2014
Wednesday, May 25, 2011
Investopedia: Autodesk Still At The Drawing Board
Going back to the drawing board is supposed to be a bad a thing - a mark of failure that comes after a plan does not quite work out as expected. For Autodesk (Nasdaq:ADSK), it's just another day on the job for this leading provider of design and digital content software, including the very well-known AutoCad software, which is a leader in drafting, design and architectural drawing.
Read the full article at Investopedia:
http://stocks.investopedia.
With the economic recovery in full swing, the question for Autodesk investors now is what the company can do to leverage its extensive brand value into new growth opportunities. The answer to that question may well spell the difference between an underappreciated growth opportunity and yet another well-known, old-school tech stock destined to languish.
A Solid Start to the Year
Autodesk got the year off to a good start. Revenue rose 11%, with license revenue rising 15% and making up more than 60% of total revenue. Looking at the company's segments, there was a pretty remarkable conformity. The platforms, manufacturing and design business all grew around 15% for the period. In contrast, weak infrastructure and commercial construction activity is keeping a lid on the AEC (architecture, engineering and construction) business, and growth here was just 3% for the quarter.
Read the full article at Investopedia:
http://stocks.investopedia.
Subscribe to:
Posts (Atom)